Related references
Note: Only part of the references are listed.Long-term treatment with testosterone undecanoate injections in men with hypogonadism alleviates erectile dysfunction and reduces risk of major adverse cardiovascular events, prostate cancer, and mortality
Farid Saad et al.
AGING MALE (2020)
A cost-utility analysis of phosphodiesterase type 5 inhibitors in the treatment of erectile dysfunction
Svenn Alexander Hansen et al.
EUROPEAN JOURNAL OF HEALTH ECONOMICS (2020)
The first-generation phosphodiesterase 5 inhibitors and their pharmacokinetic issue
A. Zucchi et al.
ANDROLOGY (2019)
Quantitation of tadalafil in human plasma using a sensitive and rapid LC-MS/MS method for a bioequivalence study
Abhaysingh Bhadoriya et al.
JOURNAL OF PHARMACEUTICAL ANALYSIS (2018)
Efficacy of Once-Daily Administration of Udenafil for 24 Weeks on Erectile Dysfunction: Results from a Randomized Multicenter Placebo-Controlled Clinical Trial
Ki Hak Moon et al.
JOURNAL OF SEXUAL MEDICINE (2015)
Avanafil for the Treatment of Erectile Dysfunction: A Multicenter, Randomized, Double-Blind Study in Men With Diabetes Mellitus
Irwin Goldstein et al.
MAYO CLINIC PROCEEDINGS (2012)
Detection and Validated Quantification of the Phosphodiesterase Type 5 Inhibitors Sildenafil, Vardenafil, Tadalafil, and 2 of Their Metabolites in Human Blood Plasma by LC-MS/MS-Application to Forensic and Therapeutic Drug Monitoring Cases
Kristina Y. Rust et al.
THERAPEUTIC DRUG MONITORING (2012)
Rapid and Sensitive Determination of Udenafil in Plasma by LC-MS/MS for Intranasal Pharmacokinetic Study in Rats
Wan-Sung Ku et al.
CHEMICAL & PHARMACEUTICAL BULLETIN (2011)
Development and validation of a GC/MS method for the determination of tadalafil in whole blood
Panagiota Nikolaou et al.
JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS (2011)
Tolerability and Pharmacokinetics of Avanafil, a Phosphodiesterase Type 5 Inhibitor: A Single- and Multiple-Dose, Double-Blind, Randomized, Placebo-Controlled, Dose-Escalation Study in Healthy Korean Male Volunteers
Jinah Jung et al.
CLINICAL THERAPEUTICS (2010)
Efficacy and Tolerability of Lodenafil Carbonate for Oral Therapy of Erectile Dysfunction: A Phase III Clinical Trial
Sidney Glina et al.
JOURNAL OF SEXUAL MEDICINE (2010)
Simple and sensitive LC-ESI-MS method for the quantitation of sildenafil in plasma samples
Khalid M. Alkharfy
JOURNAL OF SEPARATION SCIENCE (2009)
Efficacy and Tolerability of Lodenafil Carbonate for Oral Therapy in Erectile Dysfunction: A Phase II Clinical Trial
Sidney Glina et al.
JOURNAL OF SEXUAL MEDICINE (2009)
Efficacy and safety of oral SK3530 for the treatment of erectile dysfunction in Korean men: a multicenter, randomized, double-blind, placebo-controlled, fixed dose, parallel group clinical trial
Jae-Seung Paick et al.
ASIAN JOURNAL OF ANDROLOGY (2008)
Safety, tolerability and pharmacokinetics of udenafil, a novel PDE-5 inhibitor, in healthy young Korean subjects
Bo-Hyung Kim et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2008)
Efficacy and Safety of Mirodenafil, A New Oral Phosphodiesterase Type 5 Inhibitor, for Treatment of Erectile Dysfunction
Jae-Seung Paick et al.
JOURNAL OF SEXUAL MEDICINE (2008)
Evaluation of the efficacy and safety of once-a-day dosing of tadalafil 5 mg and 10 mg in the treatment of erectile dysfunction:: Results of a multicenter, randomized, double-blind, placebo-controlled trial
Hartmut Porst et al.
EUROPEAN UROLOGY (2006)
Efficacy of tadalafil for the treatment of erectile dysfunction at 24 and 36 hours after dosing: A randomized controlled trial
H Porst et al.
UROLOGY (2003)
The efficacy and tolerability of vardenafil, a new, oral, selective phosphodiesterase type 5 inhibitor, in patients with erectile dysfunction: the first at-home clinical trial
H Porst et al.
INTERNATIONAL JOURNAL OF IMPOTENCE RESEARCH (2001)
Share Paper
